Research & Development
Explore Life Science, Innovate Cancer Precision Therapy
APS03118 global clinical study plan
APS03118 is the second generation of selective RET inhibitor that independently developed by APS. APS03118 is a potential best-in-class program with stronger anti-tumor activity and better tolerability compared to other RET inhibitors in preclinical internal head-to-head studies. APS has applied for a phase I/II clinical trial in US FDA for RET positive patients with advanced solid tumors, and is preparing for the Clinical trial application of NMPA in China


   

        Study No.

  Phase

              Indication

     Region

  Start time

APS-RET-101

      I/II

with   Unresectable   Locally Advanced or Metastatic Solid Tumors Harboring RET Mutations or   Fusions

   US, EU, APAC

    Jan of 2022

APS-RET-102

       I

with   Unresectable   Locally Advanced or Metastatic Solid Tumors Harboring RET Mutations or   Fusions

         China

    May of 2022


Contact

Address

Office: Philadelphia, US

Office: Building 10-1, No.2 Jingyuan North Street, BDA, Beijing, China

Tel

+1-484-222-1342 +86-10-67860673

Mobile Mode
Copyright © 2022 All Rights Reserved Applied Pharmaceutical Science
Terms of Use

Loading...

Privacy policy

Loading...